Please find attached the Financial Results for FY ended on March 31, 2026

Management Changes View source PDF Explain this filing

NATCAPSUQ · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-3.5%Reaction day

₹169.99

prior close

₹160.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.6%-2.9% vs market

Pharmaceuticals peers, median of 162sector-0.5%-3.1% vs sector

On the reaction day the stock moved 2.9 pts less than Nifty Microcap 250 and 3.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+3.7

10m

+2.5

15m

+2.5

30m

+1.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-3.5-0.6-2.9-0.5-3.1

Next day

-7.1-1.7-5.3-1.2-5.9

-7.8-0.7-7.2-1.5-6.4

-7.1-0.4-6.7-1.6-5.5

-8.6+0.4-9.0-1.1-7.5

-7.3+0.4-7.8-1.3-6.0

-8.2+0.3-8.5-0.7-7.5

15d

-5.3+5.5-10.8+1.3-6.6

-10.4+4.6-15.0+2.6-12.9

-13.5+5.3-18.8+5.3-18.8

+24.1+11.6+12.6+6.8+17.3

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 162Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Natural Capsules Limited reported FY2026 standalone net profit of Rs.1,121.39 lakhs, up 67.1% from Rs.671.11 lakhs in FY2025, with revenue from operations at Rs.17,377.09 lakhs. Consolidated profit stood at Rs.1,707.36 lakhs. The Board approved re-appointment of Whole-time Director Mr. Laxminarayan Moondra for 3 years (effective July 28, 2026, subject to shareholder approval), appointed M/s. Mallya & Mallya as Internal Auditor for FY2026-27, and appointed Mr. Akshay Dutta as Company Secretary & Compliance Officer effective May 27, 2026. The company also allotted 25,000 equity shares under ESOP 2025 at Rs.10 per share, increasing paid-up capital to Rs.10,41,11,540. Auditors P. Chandrasekar LLP issued an unmodified opinion. One manufacturing unit was temporarily shut from December 26 to January 30, 2026 due to regulatory issues.

Likely market impact

Strong financial performance with 67% profit growth; ESOP allotment and management appointments are routine. No governance red flags detected.